Hainan Huluwa Pharmaceutical Group Co., Ltd.

Symbol: 605199.SS

SHH

11.68

CNY

Market price today

  • 51.1868

    P/E Ratio

  • -15.8679

    PEG Ratio

  • 4.67B

    MRK Cap

  • 0.00%

    DIV Yield

Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199-SS) Financial Statements

On the chart you can see the default numbers in dynamics for Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS). Companys revenue shows the average of 1066.085 M which is 0.196 % gowth. The average gross profit for the whole period is 618.62 M which is 0.274 %. The average gross profit ratio is 0.559 %. The net income growth for the company last year performance is 0.188 % which equals 0.560 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Hainan Huluwa Pharmaceutical Group Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.313. In the realm of current assets, 605199.SS clocks in at 1247.257 in the reporting currency. A significant portion of these assets, precisely 480.369, is held in cash and short-term investments. This segment shows a change of -0.015% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 20.096, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 178.404 in the reporting currency. This figure signifies a year_over_year change of 0.370%. Shareholder value, as depicted by the total shareholder equity, is valued at 1013.888 in the reporting currency. The year over year change in this aspect is 0.092%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 527.121, with an inventory valuation of 213.56, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 156.66. Account payables and short-term debt are 139.92 and 505.58, respectively. The total debt is 683.98, with a net debt of 203.61. Other current liabilities amount to 149.21, adding to the total liabilities of 1296.79. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

1221.3480.4487.7345.9
154.1
181.5
82.6
62.2

balance-sheet.row.short-term-investments

16.17005
0
0
0
0

balance-sheet.row.net-receivables

2348.68527.1371.5424
240.5
216.8
117.2
74.3

balance-sheet.row.inventory

1147.32213.6213.2186
150.9
168.9
116.3
81.9

balance-sheet.row.other-current-assets

148.9326.214.43.8
0.8
4.1
4.7
1.7

balance-sheet.row.total-current-assets

4866.221247.31086.8959.6
546.3
571.2
320.7
220.1

balance-sheet.row.property-plant-equipment-net

3861.45802.6529.4416.8
415.9
426.8
383.1
202.4

balance-sheet.row.goodwill

19.97000
0
0
0
0

balance-sheet.row.intangible-assets

745.34156.7135.6129
82.7
92.1
102.6
110.3

balance-sheet.row.goodwill-and-intangible-assets

765.31156.7135.6129
82.7
92.1
102.6
110.3

balance-sheet.row.long-term-investments

61.0920.100
1
0
0
0.5

balance-sheet.row.tax-assets

25.395.18.115.1
1.5
0.9
0.6
0.7

balance-sheet.row.other-non-current-assets

282.5780.310.7
39.3
0.9
0.2
1.9

balance-sheet.row.total-non-current-assets

4995.811064.8674.1561.5
540.3
520.8
486.5
315.8

balance-sheet.row.other-assets

0000
0
0
0
0

balance-sheet.row.total-assets

9862.032312.11760.91521.2
1086.6
1092
807.2
535.9

balance-sheet.row.account-payables

764.07139.9149.1154.9
147.7
183.5
180.5
101

balance-sheet.row.short-term-debt

1706.88505.6495.1231
136.1
111.6
76.6
123.4

balance-sheet.row.tax-payables

122.0624.728.520.2
32.7
21.3
19.4
12.2

balance-sheet.row.long-term-debt-total

1839.99178.44.152
16.5
30.5
69.7
104.9

Deferred Revenue Non Current

276.4661.532.48.1
9.7
11.2
1.1
1.3

balance-sheet.row.deferred-tax-liabilities-non-current

551.62---
-
-
-
-

balance-sheet.row.other-current-liab

259.01149.28.610.8
41
80.4
41.5
30.1

balance-sheet.row.total-non-current-liabilities

2123.13239.936.560.2
43.8
90.7
106.7
106.2

balance-sheet.row.other-liabilities

0000
0
0
0
0

balance-sheet.row.capital-lease-obligations

0.790.84.10.6
17.7
0
0
0

balance-sheet.row.total-liab

5547.371296.8830.4604.7
442.7
487.4
455.8
407.3

balance-sheet.row.preferred-stock

0000
0
0
0
0

balance-sheet.row.common-stock

1600.44400.1400.1400.1
360
360
112
60

balance-sheet.row.retained-earnings

1241.34265.5187.3181.9
78.1
50.4
30.4
9.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

812.1457.750.243.9
52.5
0
0
0

balance-sheet.row.other-total-stockholders-equity

581.13290.6290.6290.6
153.4
194.2
209
59.1

balance-sheet.row.total-stockholders-equity

4235.041013.9928.2916.5
643.9
604.6
351.4
128.7

balance-sheet.row.total-liabilities-and-stockholders-equity

9862.032312.11760.91521.2
1086.6
1092
807.2
535.9

balance-sheet.row.minority-interest

79.611.42.30
0
0
0
0

balance-sheet.row.total-equity

4314.661015.3930.5916.5
643.9
604.6
-
-

balance-sheet.row.total-liabilities-and-total-equity

9862.03---
-
-
-
-

Total Investments

77.2620.105
1
0
0
0.5

balance-sheet.row.total-debt

3546.87684499.2283
152.6
142.1
146.3
228.3

balance-sheet.row.net-debt

2325.57203.611.5-62.9
-1.5
-39.4
63.7
166.1

Cash Flow Statement

The financial landscape of Hainan Huluwa Pharmaceutical Group Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -3.371. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 326.9 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -411599698.910 in the reporting currency. This is a shift of 2.515 from the previous year. In the same period, the company recorded 51.03, 0, and -501.79, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -14.35 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 680.29, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

cash-flows.row.net-income

91.384.769.6121.5
120.3
100.5
22.1
33.8

cash-flows.row.depreciation-and-amortization

13.495148.243.5
41.5
35.5
28.6
28.4

cash-flows.row.deferred-income-tax

037-13.6
-0.6
0
0
0

cash-flows.row.stock-based-compensation

0-3-713.6
0.6
0
0
0

cash-flows.row.change-in-working-capital

-251.1178.8-35.6-182.8
-34.8
-114.6
-36.8
-12.6

cash-flows.row.account-receivables

-245.05-245.1-34.2-197.5
-45.7
0
0
0

cash-flows.row.inventory

-6.06-6.1-28.8-35.8
16.7
-57.8
-35.9
-10.5

cash-flows.row.account-payables

0326.920.464.1
-5.2
0
0
0

cash-flows.row.other-working-capital

037-13.6
-0.6
-56.7
-1
-2.1

cash-flows.row.other-non-cash-items

64.0624.120.421.1
17.4
10.3
76.1
15.4

cash-flows.row.net-cash-provided-by-operating-activities

-82.27000
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-697.22-392.3-137.6-59.4
-58.4
-72.8
-157.6
-41

cash-flows.row.acquisitions-net

-34.850.30.10.1
58.4
0.1
-0.2
0

cash-flows.row.purchases-of-investments

-110-210-14-209
-250
-115.1
-299
-108.5

cash-flows.row.sales-maturities-of-investments

110190.514.1210.7
253.1
117.7
299.7
108.6

cash-flows.row.other-investing-activites

0.03020.3-20
-58.4
0.8
30
-22.6

cash-flows.row.net-cash-used-for-investing-activites

-732.03-411.6-117.1-77.6
-55.3
-69.4
-127.1
-63.4

cash-flows.row.debt-repayment

-684.84-501.8-238.6-98.9
-68.5
-145
-208.1
-216.2

cash-flows.row.common-stock-issued

0000
-4
0
0
0

cash-flows.row.common-stock-repurchased

0000
4
0
0
0

cash-flows.row.dividends-paid

-23.06-14.4-73.7-8
-85.6
-80.6
-13.5
-15.3

cash-flows.row.other-financing-activites

1274.91680.3458.6368
40.6
359
282.3
267.3

cash-flows.row.net-cash-used-provided-by-financing-activities

567164.1146.3261.1
-113.5
133.4
60.7
35.8

cash-flows.row.effect-of-forex-changes-on-cash

254.79000
0
0
0
0

cash-flows.row.net-change-in-cash

7.49-8.7131.7186.8
-24.3
95.8
23.6
37.3

cash-flows.row.cash-at-end-of-period

1181.45463.8472.6340.9
154.1
178.4
82.6
59

cash-flows.row.cash-at-beginning-of-period

1173.96472.6340.9154.1
178.4
82.6
59
21.6

cash-flows.row.operating-cash-flow

-82.27238.7102.53.3
144.5
31.8
90
65

cash-flows.row.capital-expenditure

-697.22-392.3-137.6-59.4
-58.4
-72.8
-157.6
-41

cash-flows.row.free-cash-flow

-779.49-153.6-35.1-56.1
86.1
-41
-67.6
24

Income Statement Row

Hainan Huluwa Pharmaceutical Group Co., Ltd.'s revenue saw a change of 0.119% compared with the previous period. The gross profit of 605199.SS is reported to be 876.46. The company's operating expenses are 753, showing a change of 4.130% from the last year. The expenses for depreciation and amortization are 51.03, which is a 0.608% change from the last accounting period. Operating expenses are reported to be 753, which shows a 4.130% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.037% year-over-year growth. The operating income is 96.62, which shows a -0.037% change when compared to the previous year. The change in the net income is 0.188%. The net income for the last year was 85.68.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

income-statement-row.row.total-revenue

1736.4215151353.81161.7
1305.9
983.8
655
487.4

income-statement-row.row.cost-of-revenue

863.67638.6545.1443.7
496.8
380
337
291.2

income-statement-row.row.gross-profit

872.74876.5808.7718.1
809.1
603.8
318
196.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0

income-statement-row.row.research-development

67.83---
-
-
-
-

income-statement-row.row.selling-general-administrative

31.03---
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

577.31---
-
-
-
-

income-statement-row.row.other-expenses

50.2547.853.911.2
25
1.9
1.2
5.7

income-statement-row.row.operating-expenses

720.22753723.1564.1
650.7
477.7
269
144.2

income-statement-row.row.cost-and-expenses

1583.91391.61268.21007.8
1147.5
857.7
606
435.4

income-statement-row.row.interest-income

2.5523.80.9
0.2
0.4
0.9
-0.8

income-statement-row.row.interest-expense

20.191813.99.1
13.4
8.9
14.5
11.4

income-statement-row.row.selling-and-marketing-expenses

577.31---
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.840.6-18.60.2
0.7
-7.6
-13.6
-8.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-

income-statement-row.row.other-operating-expenses

50.2547.853.911.2
25
1.9
1.2
5.7

income-statement-row.row.total-operating-expenses

0.840.6-18.60.2
0.7
-7.6
-13.6
-8.9

income-statement-row.row.interest-expense

20.191813.99.1
13.4
8.9
14.5
11.4

income-statement-row.row.depreciation-and-amortization

30.777.548.263.9
61.4
35.5
28.6
28.4

income-statement-row.row.ebitda-caps

150.19---
-
-
-
-

income-statement-row.row.operating-income

119.4996.6100.3134.2
141.6
116.6
34.2
37.4

income-statement-row.row.income-before-tax

120.3397.281.7134.4
142.2
118.5
35.4
43.1

income-statement-row.row.income-tax-expense

24.2212.512.112.9
21.9
17.9
13.3
9.3

income-statement-row.row.net-income

91.385.772.1121.5
120.3
100.5
22.1
33.8

Frequently Asked Question

What is Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) total assets?

Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) total assets is 2312057375.000.

What is enterprise annual revenue?

The annual revenue is 750710777.000.

What is firm profit margin?

Firm profit margin is 0.503.

What is company free cash flow?

The free cash flow is -1.948.

What is enterprise net profit margin?

The net profit margin is 0.053.

What is firm total revenue?

The total revenue is 0.069.

What is Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) net profit (net income)?

The net profit (net income) is 85681971.000.

What is firm total debt?

The total debt is 683982174.000.

What is operating expences number?

The operating expences are 752999742.000.

What is company cash figure?

Enretprise cash is 183771492.000.